Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
Top Cited Papers
Open Access
- 1 April 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (4), 545-553
- https://doi.org/10.1001/jamaoncol.2017.5524
Abstract
Almost all women with estrogen receptor (ER)–positive primary breast cancer are offered adjuvant endocrine therapy, and a highly relevant clinical question is who remains at high risk for distant recurrence despite completion of primary adjuvant therapy. Multigene expression profiles have significantly increased our ability to estimate distant recurrence in ER-positive breast cancer after surgery and endocrine treatment.1 These signatures are used in combination with different clinical characteristics to aid the selection of patients for whom chemotherapy may be appropriate based on prognosis. Several of these signatures are commercially available, including the Oncotype Dx recurrence score (RS) (Genomic Health), PAM50-based Prosigna risk of recurrence (ROR) (NanoString), Breast Cancer Index (BCI) (bioTheranostics), EndoPredict (EPclin) (Myriad Genetics), and MammaPrint Netherland Kanker Institute 70-gene signature (Agendia BV), are endorsed by several guidelines2-5 and are routinely used by clinicians.Keywords
This publication has 28 references indexed in Scilit:
- Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant RecurrenceClinical Cancer Research, 2013
- Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical FactorsJournal of Clinical Oncology, 2011
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast CancerJournal of Clinical Oncology, 2011
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk FactorsClinical Cancer Research, 2011
- Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trialBritish Journal of Cancer, 2011
- Gene-Expression Signatures in Breast CancerThe New England Journal of Medicine, 2009
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesBreast Cancer Research, 2008
- A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast CancerClinical Cancer Research, 2008
- Sorting Out Breast-Cancer Gene SignaturesThe New England Journal of Medicine, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004